Cryopreservation Options to Preserve Fertility in Female Cancer Patients: Available Clinical Practice and Investigational Strategies from the Oncology Guidelines Point of View

L. Mirzaeian, Haniyeh Rafipour, S. Hashemi, S. Zabihzadeh, S. Amanpour
{"title":"Cryopreservation Options to Preserve Fertility in Female Cancer Patients: Available Clinical Practice and Investigational Strategies from the Oncology Guidelines Point of View","authors":"L. Mirzaeian, Haniyeh Rafipour, S. Hashemi, S. Zabihzadeh, S. Amanpour","doi":"10.18502/BCCR.V12I1.5726","DOIUrl":null,"url":null,"abstract":"In recent years, advances in cancer treatment have improved the survival rate of cancer patients significantly. However, destructive damage to ovaries due to the therapies or cancer itself can cause different degrees of infertility in women of reproductive age that can affect their quality of life seriously. In this study, fertility cryopreservation options for female cancer patients in oncology guidelines were reviewed. Cryopreservation methods have a long history in reproductive biology and oncology. However, embryo and oocyte cryopreservation were the eligible restoration strategies in clinical oncology practice. Ovarian tissue cryopreservation (OTC) is the latest option recommended for fertility preservation in pre-pubertal and adult patients who cannot delay their treatment or in whom taking IVF hormones may have adverse effects on their cancer. Reports show that frozen-thawed ovarian tissue transplantation has led to more than 130 live births so far in patients, most of whom were cancer patients. Although OTC is indeed generally recognized as an investigational method, it is recommended in some important guidelines, such as ASCO 2018. Therefore, based on many clinical pieces of evidence , it is predicted that the investigational label will soon be removed, and OTC might be considered as one of the main fertility preservation options for female cancer patients in clinical oncology practice.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/BCCR.V12I1.5726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

In recent years, advances in cancer treatment have improved the survival rate of cancer patients significantly. However, destructive damage to ovaries due to the therapies or cancer itself can cause different degrees of infertility in women of reproductive age that can affect their quality of life seriously. In this study, fertility cryopreservation options for female cancer patients in oncology guidelines were reviewed. Cryopreservation methods have a long history in reproductive biology and oncology. However, embryo and oocyte cryopreservation were the eligible restoration strategies in clinical oncology practice. Ovarian tissue cryopreservation (OTC) is the latest option recommended for fertility preservation in pre-pubertal and adult patients who cannot delay their treatment or in whom taking IVF hormones may have adverse effects on their cancer. Reports show that frozen-thawed ovarian tissue transplantation has led to more than 130 live births so far in patients, most of whom were cancer patients. Although OTC is indeed generally recognized as an investigational method, it is recommended in some important guidelines, such as ASCO 2018. Therefore, based on many clinical pieces of evidence , it is predicted that the investigational label will soon be removed, and OTC might be considered as one of the main fertility preservation options for female cancer patients in clinical oncology practice.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
冷冻保存选择以保持女性癌症患者的生育能力:从肿瘤学指南的角度来看,可用的临床实践和研究策略
近年来,癌症治疗的进步显著提高了癌症患者的生存率。然而,由于治疗或癌症本身对卵巢的破坏性损伤可导致育龄妇女不同程度的不孕症,严重影响她们的生活质量。本研究综述了肿瘤学指南中女性癌症患者生育能力冷冻保存的选择。低温保存方法在生殖生物学和肿瘤学领域有着悠久的历史。然而,胚胎和卵母细胞冷冻保存是临床肿瘤实践中合适的恢复策略。卵巢组织冷冻保存(OTC)是最新推荐的生育能力保存的选择,在青春期前和成年患者不能延迟他们的治疗或服用体外受精激素可能对他们的癌症有不利影响。报告显示,迄今为止,冷冻解冻卵巢组织移植已导致130多名患者活产,其中大多数是癌症患者。虽然OTC确实被普遍认为是一种研究方法,但在一些重要的指南(如ASCO 2018)中推荐使用。因此,基于许多临床证据,我们预测该临床标签将很快被移除,OTC可能被认为是临床肿瘤学实践中女性癌症患者的主要生育能力保存选择之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊最新文献
The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects Chronic Myeloid Leukemia in a Young Man with Unusual Presentation of Weight Loss, Bone Pain, and Abdominal Pain Effects of Gold Nanoparticles on Proton Therapy for Breast Cancer Cancer has an Independent Association with Death in Hospitalized Patients with COVID-19: A Single-center Study in Iran
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1